

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Mega Genomics Limited**  
**美因基因有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 6667)**

**QUARTERLY UPDATE ON RESUMPTION PROGRESS**  
**POSTPONEMENT OF ANNUAL GENERAL MEETING**  
**AND**  
**CONTINUED SUSPENSION OF TRADING**

This announcement is made by Mega Genomics Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated 1 April 2025, 22 April 2025, 30 April 2025, 5 May 2025, 30 May 2025 and 10 June 2025 (the “**Announcements**”) in relation to, among other matters, (i) delay in publication of the 2024 Annual Results, (ii) postponement of the Board meeting, (iii) delay in publication of the 2024 Annual Report, (iv) proposed change of the auditor; and (v) resumption guidance from the Stock Exchange. Unless otherwise defined or the context otherwise requires, capitalised terms in this announcement shall have the same meanings as defined in the Announcements.

The Company wishes to inform its Shareholders and potential investors of the progress of actions recently taken by the Company in connection with fulfilling the Resumption Guidance and the latest development of the Group’s business operations.

## **UPDATE OF BUSINESS OPERATIONS**

The Group is a leading genetic testing platform company in China, principally engaged in providing customers with consumer genetic testing services and cancer screening services. Since the suspension of trading in the shares of the Company and up to the date of this announcement, the Group has been carrying on its business operations as usual in all material. As at 31 March 2025, the Group has collaborated with nearly 1,950 healthcare institutions in more than 340 cities in China, and has conducted a total of nearly 24 million genetic tests.

## **INDEPENDENT INVESTIGATION**

As disclosed in the Company's announcement dated 22 April 2025, the Board has resolved to establish the Investigation Committee. As at the date of this announcement, the Company has engaged an independent investigation company to commence an independent investigation. The Company has been actively assisting the investigation company in the course of investigation under the overall supervision of the Investigation Committee. The independent investigation is now in progress, and the preliminary draft of the independent investigation report is expected to be completed shortly. The Company will make further announcement(s) to update the Shareholders and potential investors on the latest progress of the independent investigation as and when necessary.

## **APPOINTMENT OF FINANCIAL ADVISER**

The Company has appointed a financial adviser to assist in the resumption process. The financial adviser is actively providing strategic guidance on compliance with the Listing Rules and working closely with the Company to formulate a practicable resumption plan.

## **INTERNAL CONTROL REVIEW**

The Company is seeking to engage an external independent adviser with adequate experience and qualifications for an internal control review to assess the effectiveness and efficiency of the Group's internal control environment and to provide the Company with recommendations for improvement and/or remedies, so as to address the weakness and deficiencies (if any) in the internal control system identified in the internal control review.

## **RESUMPTION PLAN**

In order to satisfy the Resumption Guidance, the Company is working with its professional advisers on formulating the resumption plan, which contains the actions it intends to take to address the matters that have led to its suspension of trading and to satisfy the Resumption Guidance, and continues to endeavor to satisfy the requirements of the Resumption Guidance. The Company will seek to resume trading in its shares on the Stock Exchange as soon as possible. Further announcement(s) will be made by the Company to update the Shareholders and the public on, among other things, the progress of the resumption plan of the Company as and when appropriate.

## **POSTPONEMENT OF ANNUAL GENERAL MEETING**

Pursuant to Rule 13.46(2)(b) of the Listing Rules, the Company should lay its annual financial statements before its shareholders at its annual general meeting within the period of six months after the end of the financial year or accounting reference period to which the annual financial statements relate (i.e., on or before 30 June 2025). Due to the matters set out in the Announcements, the despatch of the 2024 Annual Report is still pending as of the date of this announcement. It is expected that the convening of the annual general meeting of the Company will be postponed beyond six months from the financial year end date. The Company will publish further announcement(s) to inform its shareholders of the date of the annual general meeting of the Company as and when appropriate.

## **PROPOSED CHANGE OF AUDITOR**

As disclosed in the Company's announcement dated 5 May 2025 and the circular dated 30 June 2025 (the "**Circular**"), the Board has resolved to propose the dismissal of Ernst & Young and the appointment of Crowe (HK) CPA Limited as the new auditor of the Company. Please refer to the Circular for further details.

## **CONTINUED SUSPENSION OF TRADING**

At the request of the Company, trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on 1 April 2025 and will remain suspended until further notice. Further announcement(s) will be made by the Company as and when appropriate and in accordance with the Listing Rules.

**Shareholders and prospective investor are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**Mega Genomics Limited**  
**LIN Lin**  
*Executive Director and Chairperson*

Hong Kong, 30 June 2025

*As of the date of this announcement, the executive Directors are Dr. Yu Rong, Ms. Lin Lin and Ms. Jiang Jing; the non-executive Director is Ms. Guo Meiling; and the independent non-executive Directors are Dr. Zhang Ying, Mr. Jia Qingfeng and Dr. Xie Dan.*

\* *For identification purpose only*